What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 0 · 0%Moderate 3 · 60%High 1 · 20%

Summary of findings ‐ nebulised azithromycin vs azithromycin

Adverse events: number of treatment‐related adverse events · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

Summary of findings ‐ weekly azithromycin vs daily azithromycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.77 [1.03, 3.04]
1 study · 268 participants
Moderate

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High

Oral azithromycin vs placebo

Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 748 participants
Moderate